LUND, SWEDEN–(Marketwire – Oct 19, 2012) – Active Biotech (NASDAQ OMX NORDIC: ACTI) today
announces that its partner Ipsen (Euronext: IPN; ADR: IPSEY, read press
here) will initiate a new phase II, proof-of-concept clinical trial
tasquinimod in a so-called umbrella study evaluating the compound in
different tumor types.
Read more from the original source: Active Biotech’s partner Ipsen initiates a proof-of-concept study with tasquinimod in additional cancer indications